Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
Rhea-AI Summary
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotech focused on PLK1 inhibition in cancer, will participate in the Jefferies Global Healthcare Conference from June 2-4, 2026. Management will join a fireside chat and 1x1 investor meetings.
The fireside chat with President and CEO Mani Mohindru, PhD is scheduled for June 4, 2026, from 10:30-11:00 AM ET. A live webcast and replay will be available via the Events section of the Cardiff Oncology website.
Positive
- None.
Negative
- None.
News Market Reaction – CRDF
In the Jun 2 session, CRDF gained 2.03%, reflecting a moderate positive market reaction. Argus tracked a trough of -23.1% from its starting point during tracking. Our momentum scanner triggered 39 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 21 | Clinical webcast notice | Positive | -0.6% | Announced investor webcast to review updated Phase 2 CRDF-004 data. |
| May 14 | Earnings and update | Positive | -3.5% | Reported Q1 2026 results, positive Phase 2 data, and cash runway into Q1 2027. |
| Apr 28 | Inducement grant | Neutral | -3.6% | Announced 400,000 stock options inducement grant for new COO. |
| Apr 27 | KOL webinar | Positive | +0.0% | Planned key opinion leader webinar on single-agent onvansertib activity in CMML. |
| Apr 21 | ASCO Phase 2 update | Positive | -7.3% | Planned updated Phase 2 onvansertib data presentation at ASCO 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and business communications often coincided with negative next-day price reactions, even when updates were constructive.
Over the last several months, Cardiff Oncology has focused newsflow on advancing onvansertib in RAS‑mutated metastatic colorectal cancer and strengthening leadership. Updates on ASCO 2026 presentations and an investor webcast, Q1 2026 earnings with a cash runway into Q1 2027, and key opinion leader events have all been followed by flat to negative price moves, including a -7.3% reaction to an ASCO rapid oral presentation announcement. Today’s conference participation fits this pattern of frequent investor‑facing events around clinical milestones.
Key Terms
1x1 investor meetings financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies Global Healthcare Conference on June 2-4, 2026.
Details of the presentation can be found below.
Format: Fireside Chat
Presenter: Mani Mohindru, PhD (President and CEO)
Date: 06/04/2026
Time: 10:30 -11:00 AM ET
Interested parties can register for and access the live webcast for the conference by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.
For more information, please visit https://www.cardiffoncology.com.
Investor Contact:
Candice Masse
Astr Partners
candice.masse@astrpartners.com
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
